Millennium Management
ACTU

Millennium Management’s Actuate Therapeutics ACTU Stock Holding History

Millennium Management’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,185
Closed -$82.5K – 6437
2025
Q1 		$82.5K Buy
+12,185
New +$97.8K ﹤0.01% 5464

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NU
Northwestern University Evanston, Illinois $63.3M AUM 0.76% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

Millennium Management's ACTU Position: Q2 2025 in Review

Millennium Management sold out of Actuate Therapeutics (ACTU) in Q2 2025, closing a stake of 12,185 shares — an estimated $82.5K sold.

Millennium Management first reported a position in ACTU in Q1 2025 and held it in 1 quarter. The position peaked at $82.5K in Q1 2025. 38 funds tracked by Wall St. Rank hold ACTU as of Q2 2025.

  • Millennium Management reported no remaining Actuate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 12,185 Actuate Therapeutics shares in Q2 2025, an estimated $82.5K.
  • Millennium Management first reported a position in Actuate Therapeutics in Q1 2025 and held it in 1 quarter.
  • Millennium Management's Actuate Therapeutics position peaked at $82.5K in Q1 2025.
  • 38 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.